Diagnostik interstitieller Lungenerkrankungen – Handlungsempfehlung mit Fokus auf rheumatologische Systemerkrankungen

Interstitielle Lungenerkrankungen (ILD) können im Rahmen rheumatologischer Systemerkrankungen auftreten und müssen bei Verdacht durch detaillierte Diagnostik detektiert werden. Besonders kritisch ist das Auftreten von akuten Exazerbationen, die während eines Progresses der ILD auftreten und mit einer erheblichen Mortalität verbunden sind. Eine interdisziplinär entwickelte Leitlinie gibt Handlungsempfehlungen für die IDL-Diagnostik.

Abstract

Interstitial lung diseases (ILD) are etiologically heterogeneous with unknown and known causes like rheumatologic systemic diseases differing in their therapeutic and prognostic consequences. In consensus between pulmonologists, rheumatologists, radiologists, and pathologists, we developed practical instructions for ILD diagnosis in rheumatologic systemic diseases, in particular because ILD can present in early stages of rheumatic systemic diseases. ILD diagnosis is based on clinical assessment results including a detailed medical history, physical examination, focused laboratory tests, radiology with a high-resolution computed tomography, lung function, and histopathology also to differentiate it from cardiac and infection associated lung diseases. The ILD diagnosis is made in a multidisciplinary discussion leading to therapeutic and prognostic consequences. The occurrence of acute exacerbations is especially critical. They are often the causes for ILD progression and are associated with considerable mortality.

Schlüsselwörter

interstitielle Lungenerkrankung - rheumatologische Systemerkrankung - diagnostische Handlungsempfehlung - Lungenfibrose - diffuse Lungenparenchym-Erkrankung

Key words

interstitial lung disease - rheumatoid systemic disease - diagnostic recommendation - lung fibrosis - diffuse parenchymal lung disease

Publication History

Article published online:
24 October 2022

• Literatur

• 1 Bastian H, Krause A. Rheuma und Lunge. DMW 2021; 146: 752-756
• 2 American Thoracic Society; European Respiratory Society. American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias. This joint statement of the American Thoracic Society (ATS), and the European Respiratory Society (ERS) was adopted by the ATS board of directors, June 2001 and by the ERS Executive Committee, June 2001. Am J Respir Crit Care Med 2002; 165: 277-304
• 3 Antoniou KM, Margaritopoulos GA, Tomassetti S. et al. Interstitial lung disease. Eur Respir Review 2014; 23: 40-54
• 4 European Respiratory Society. Interstitial lung diseases, Capter 22. Im Internet (Stand: 28.06.2022): https://www.erswhitebook.org/chapters/interstitial-lung-diseases/
• 5 Fischer A, Antoniou KM, Brown KK. et al. An official European Respiratory Society/American Thoracic Society research statement: interstitial pneumonia with autoimmune features. Eur Respir J 2015; 46: 976-987
• 6 Luppi F, Sebastiani M, Salvarani C. et al. Acute exacerbation of interstitial lung disease associated with rheumatic disease. Nat Rev Rheumatol 2021; 18: 85-96
• 7 Lee H, Choi H, Yang B. et al. Interstitial lung disease increases susceptibility to and severity of COVID-19. Eur Respir J 2021; 58: 2004125
• 8 Valenzuela C, Waterer G, Raghu G. Interstitial lung disease before and after COVID-19: a double threat?. Eur Respir J 2021; 58: 2101956
• 9 Antoniou KM, Vasarmidi E, Russell AM. et al. European Respiratory Society Statement on Long COVID-19 Follow-Up. Eur Respir J 2022; 10: 2102174
• 10 Freise J, Wehmeier P, Welte T. Arzneimittelbedingte interstitielle Lungenerkrankungen. DMW 2010; 135: 450-454
• 11 Kreuter M, Ochmann U, Koschel D. et al. Patientenfragebogen zur Erfassung der Ursachen interstitieller und seltener Lungenerkrankungen – klinische Sektion der DGP. Pneumologie 2018; 72: 446-457
• 12 Juge PA, Lee JS, Lau J. et al. Methotrexate and rheumatoid arthritis associated interstitial lung disease. Eur Respir J 2021; 57: 2000337
• 13 Bahmer T, Romagnoli M, Girelli F. et al. The use of auto-antibody testing in the evaluation of interstitial lung disease (ILD)--A practical approach for the pulmonologist. Respir Med 2016; 113: 80-92
• 14 Behr J, Günter A, Bonella F. et al. S2K-Leitlinie zur Diagnostik der idiopathischen Lungenfibrose. Pneumologie 2020; 74: 263-293
• 15 Meyer FJ, Borst MM, Buschmann HC. et al. Belastungsuntersuchungen in der Pneumologie. Pneumologie 2018; 72: 687-731
• 16 Raghu G, Remy-Jardin M, Myers JL. et al. Diagnosis of Idiopathic Pulmonary Fibrosis. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline. Am J Respir Crit Care Med 2018; 198: e44-e68
• 17 Laursen CB, Clive A, Hallifax R. et al. European Respiratory Society statement on thoracic ultrasound. Eur Respir J 2021; 57: 2001519
• 18 Hetzel J, Kreuter M, Kähler C. et al. Bronchoscopic performance of bronchoalveolar lavage in Germany – a call for standardization: A request for BAL standardization. Sarcoidosis VDLD 2021; 38: e2021003
• 19 Troy LK, Hetzel J. Lung cryobiopsy and interstitial lung disease: What is its role in the era of multidisciplinary meetings and antifibrotics?. Respirology 2020; 25: 987-996
• 20 Kurihara C, Tolly B, DeWolf A. et al. Thoracoscopic lung biopsy under regional anesthesia for interstitial lung disease. Reg Anesth Pain Med 2020; 45: 255-259